News | November 10, 2023
GSK registers 5% revenue growth in Q2 FY24
General Medicine grows 5% and Vaccines 10% led by Shingrix
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The companies plan to start a pivotal Phase 3 trial in the coming months
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Subscribe To Our Newsletter & Stay Updated
